NCT03089645View on ClinicalTrials.gov

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 21, 2017

Primary Completion Date

June 23, 2020

Study Completion Date

June 23, 2020

Conditions
Advanced Solid Tumors
Interventions
BIOLOGICAL

MEDI5083 monotherapy

Dose-escalation MEDI5083 monotherapy followed by monotherapy with Durvalumab

BIOLOGICAL

MEID5083 with Durvalumab or Tremelimumab

Sequential Medi5083 with concurrent Durvalumab or Tremelimumab, and intermittent Medi5083 with concurrent Durvalumab

BIOLOGICAL

Medi5083 with Durvalumab and Docetaxel

Medi5083 with concurrent Durvalumab and Docetaxel randomized against Durvalumab and Docetaxel

Trial Locations (8)

2031

Research Site, Randwick

3000

Research Site, Melbourne

3004

Research Site, Melbourne

3168

Research Site, Clayton

37203

Research Site, Nashville

84112

Research Site, Salt Lake City

07601-2191

Research Site, Hackensack

02903

Research Site, Providence

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY